Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma

Jen-Jung Pan¹
Milind Javle²
Mie Mie Thinn³
Chung-Tzu Hsueh⁴
Chung-Tsen Hsueh⁵

¹Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA; ²Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Division of Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA; ⁴Department, Cathay General Hospital, Taipei, Taiwan; ⁵Division of Medical Oncology and Hematology, Loma Linda University Medical Center, Loma Linda, CA, USA

Correspondence: Chung-Tsen Hsueh
Division of Medical Oncology and Hematology, Loma Linda University Medical Center, 11175 Campus, CSP 11015, Loma Linda, CA 92354, USA
Tel +1 909 558 8107
Fax +1 909 558 0219
Email chsueh@llu.edu

Abstract: Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.

Keywords: sorafenib, hepatocellular carcinoma, multiple kinase inhibitor

Introduction

Hepatocellular carcinoma (HCC) has become a global health problem, with more than half a million new cases diagnosed worldwide each year.¹ HCC is associated with a high mortality rate, and is the leading cause of liver-related death in patients with compensated cirrhosis.² The incidence of HCC is increasing in several developed countries, including the US. Between 1995 and 1998 alone, there was a 25% increase of HCC incidence in the US.³ It has been estimated that the number of cases of HCC will continue to increase by 81% to the year 2020, predominantly due to hepatitis C (HCV) infection.⁴ Nevertheless, the incidence of HCC is decreasing in some developing countries as a result of the implementation of universal hepatitis B vaccination.⁵

Older age (>50 years), male gender, severity of compensated liver cirrhosis at presentation, and sustained activity of liver disease are important predictors of HCC, independent of etiology of cirrhosis.⁶ Males typically have a two- to four-fold higher risk of developing HCC than females. Age may serve as a surrogate for the duration of underlying liver disease. More than 80% of patients with HCC have cirrhosis, which remains the major risk factor. Therefore, any cause of liver cirrhosis is associated with increased risks of HCC. HCV infection, hepatitis B (HBV) infection, and heavy alcohol use remain the most common causes of cirrhosis in Western countries.

Once the diagnosis of HCC is made and confirmed, there are several treatment options depending on the size and number of tumors, underlying liver function, presence or absence of tumor vascular invasion, and the patient’s performance status. Hepatic resection may be an option for those with HCC in a noncirrhotic liver or those with HCC and cirrhosis but without portal hypertension and with normal bilirubin. Portal hypertension is defined as the presence of hepatic venous pressure gradient...
greater than 10 mmHg, esophageal varices, or splenomegaly with a platelet count less than 100,000/mm³. Subjects without relevant portal hypertension and normal bilirubin can achieve a 70% five-year survival after hepatic resection, whereas survival is only 50% in those with portal hypertension, and even lower with both adverse factors. Hepatic resection is associated with a high tumor recurrence rate, i.e., up to 70% in five years, either from true recurrence or development of de novo tumors.

Liver transplantation is the mainstay treatment for those with HCC and cirrhosis. During transplantation, not only the tumor itself but also the cirrhotic liver that provides the background for new tumor development will be removed. For those who meet the Milan criteria (solitary HCC less than 5 cm in size or up to three tumors with each tumor less than 3 cm in size), transplantation provides a five-year survival exceeding 70% while maintaining a low recurrence rate of less than 15%. In spite of being the best option for patients with HCC, transplantation is limited by the current shortage of available donors. To avoid dropout while awaiting transplantation, transplant candidates usually receive locoregional treatments, such as transarterial chemoembolization or percutaneous ablation, especially if the waiting time exceeds six months. Due to the small risk of tumor seeding in the needle tract associated with percutaneous ablation, transarterial chemoembolization is more favored as a bridging therapy for transplant candidates.

For those with small unresectable HCC, percutaneous ablation, such as percutaneous ethanol injection and radiofrequency ablation, offers comparable survival with that of resection. In addition to similar survival compared with surgery, percutaneous ablation therapy is relatively simple, low-cost, repeatable, and safe. Compared with percutaneous ethanol injection, radiofrequency ablation has a higher rate of complete tumor necrosis (radiofrequency ablation 90% versus percutaneous ethanol injection 80%), requires fewer treatment sessions (radiofrequency ablation 1.2 versus percutaneous ethanol injection 4.8), and is associated with better local recurrence-free survival compared with percutaneous ethanol injection. Nevertheless, the incidence of adverse events is not significantly different between these two treatment modalities.

In addition to being used as a bridging therapy before transplantation, transarterial chemoembolization also serves as a palliative measure for those with unresectable HCC and who are not amenable to percutaneous ablation. In a systematic review of randomized, controlled trials involving various treatment modalities in patients with unresectable HCC, arterial embolization improved two-year survival compared with controls (odds ratio [OR] 0.53; 95% confidence interval [CI], 0.32–0.89; P = 0.017). Sensitivity analysis showed a significant benefit of transarterial chemoembolization (OR 0.42; 95% CI 0.20–0.88) but none with bland embolization alone (OR 0.59; 95% CI 0.29–1.20). Radioembolization with microspheres carrying yttrium 90 injected via the intrahepatic arterial route has been proposed as an alternative approach to transarterial chemoembolization. This method can deliver radiation to the HCC-associated capillary bed. Radioembolization requires only single-dose administration, and has been shown to be therapeutically equivalent to transarterial chemoembolization.

Patients with advanced HCC who are not candidates for local approaches are considered for systemic therapy. Systemic therapy with cytotoxic agents, such as doxorubicin, provides marginal benefits without improvement in overall survival. Investigation in hepatocarcinogenesis has led to the discovery of key molecular targets in HCC, such as angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin. A growing number of molecularly targeted therapies for HCC are currently at different stages of clinical development. Sorafenib (Nexavar®, Bayer Healthcare AG, Leverkusen, Germany), a multikinase inhibitor, is the only such drug that has been approved in the US and Europe for treatment of unresectable HCC. In this review, we provide a critical appraisal of sorafenib in the management of HCC.

**Mechanism of action and pharmacologic effects**

Sorafenib inhibits multiple tyrosine and serine/threonine kinases involved in cell proliferation and angiogenesis. These kinases include Raf kinase, vascular endothelial growth factor receptor (VEGFR) kinases, platelet-derived growth factor receptor (PDGFR) kinase, e-kit receptor kinase, RET receptor kinase, and FMS-like tyrosine kinase 3. Disruption of PDGFR and VEGFR signaling pathways inhibits angiogenesis. Raf is an essential serine/threonine kinase in the mitogen-activated protein (MAP) kinase signaling pathway, and is a downstream effector of Ras, which is activated in many human malignancies. When the Raf-MAP kinase pathway is activated, extracellular signal-regulated kinase (ERK) will become phosphorylated. Subsequently, phosphorylated ERK (pERK) can be translocated to the nucleus where it can regulate gene expression by modulating various transcription factors and target genes. Preclinical models have demonstrated that HCC exhibits activation of
MAP signaling and overexpression of angiogenesis factors. Sorafenib blocks the Raf-MAP kinase and ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in HCC cell lines.22

Pharmacodynamic assay for Raf-MAP kinase inhibition by sorafenib has been investigated in patients’ peripheral blood lymphocytes collected at different time points in a Phase I study.23 Lymphocytes were activated with phorbol myristate acetate, and flow cytometric analyses of pERK were performed. The phorbol myristate acetate-induced pERK in peripheral blood lymphocytes from six patients was almost completely eradicated by sorafenib after 21 days of the maximally tolerated dose. In a Phase II study of sorafenib in advanced HCC, immunohistochemical study in pretreatment tumor biopsies using an antibody against pERK was performed in 33 patients (of 137 enrolled patients), and pERK staining was more intense in the nuclei of tumor tissues.24 There was a significant difference in time to progression between patients with higher tumor cell pERK staining intensity versus those with lower intensity. Patients with tumors exhibiting higher pERK staining intensity had a longer time to progression. A similar finding was also noted in a retrospective biomarker analysis of the Phase III Sorafenib HCC Assessment Randomized Protocol (SHARP) trial.25 The biomarker study from the SHARP trial has further revealed that low hepatocyte growth factor and high e-kit serum levels at baseline were associated with improved survival in multivariate analysis. These findings are exploratory and require validation in perspective studies.

**Pharmacokinetics**

The recommended dose of sorafenib is 400 mg orally twice a day, and should be administered to patients who are fasting or with a moderate-fat meal. A high-fat meal reduces sorafenib’s bioavailability by about 30%. The plasma protein binding of sorafenib is about 99% in patients with normal renal and hepatic function.26 Sorafenib is primarily metabolized in the liver, predominantly via Phase I oxidation by cytochrome P450 (CYP) 3A4, and Phase II conjugation by uridine 5′-diphosphoglucuronosyltransferase.27,28 Approximately 50% of orally administered sorafenib is recovered as unchanged drug in the feces, due to either biliary excretion or lack of absorption. Urinary excretion accounts for approximately 20% of drug metabolism. The mean terminal elimination half-life of sorafenib is approximately 24–38 hours, and sorafenib exposures reach steady state within seven days of dosing.29

Because sorafenib is mainly metabolized by CYP3A4, its pharmacokinetics may be affected by drugs modulating the function of CYP3A4. Concurrent administration of rifampin, a CYP3A4 inducer, has been shown to decrease the area under the plasma concentration versus time curve (AUC) of sorafenib by 37%. Other CYP3A4 inducers, including carbamazepine, phenobarbital, and dexamethasone, may decrease the AUC of sorafenib.30 Neomycin decreases the AUC of sorafenib by 54%, probably due to eradication of gastrointestinal bacteria and therefore preventing the enterohepatic recycling of sorafenib.31 Due to potential drug interaction, patients taking medications such as warfarin, digoxin, and quinidine may require close monitoring during sorafenib treatment.26,31

It has been shown that the AUC for sorafenib is 30%–45% lower in Japanese or Chinese than in Caucasian populations, and the clinical significance of this finding remains unknown.30,32 The Child-Pugh scoring system uses clinical and laboratory information to stratify disease severity, surgical risk, and overall prognosis in patients with liver cirrhosis.33 The AUC of sorafenib in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment has been shown to be 23%–65% lower than in subjects with normal hepatic function, and there are no significant differences in sorafenib pharmacokinetics between patients with Child-Pugh A and Child-Pugh B hepatic impairment.24,34 No significant difference in sorafenib pharmacokinetics has been shown between patients with normal renal function and mild-to-moderate renal insufficiency (creatinine clearance less than 30 mL/min). In a Phase I pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction, Miller et al showed that patients with severe renal or hepatic dysfunction frequently developed intolerance to sorafenib.35 Therefore, it is recommended to start at a lower dose in these patient populations, followed by close monitoring and gradual dose escalation.

**Pivotal studies of sorafenib in HCC**

Two Phase III randomized studies, ie, SHARP and the Asia-Pacific study, comparing sorafenib with placebo as first-line systemic treatment in patients with advanced HCC, have demonstrated the efficacy of sorafenib.36,37 Patient characteristics and outcome measures of these two studies are summarized in Tables 1 and 2.

The SHARP study was designed for the regulatory approval of sorafenib in the US and Europe, and was a randomized, double-blinded, placebo-controlled, Phase III study conducted in Europe, the US, and Australasia. It enrolled
Pan et al 602 patients with advanced HCC, well-preserved liver function, and no prior systemic therapy. Patients were randomized in a 1:1 ratio to receive either oral sorafenib (400 mg twice daily) or placebo. Primary endpoints were overall survival and time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. The primary outcomes were evaluated based on the intention-to-treat principle. The number of patients needed for this study was calculated on the basis of overall survival, with a power of 90% to detect a 40% improvement in overall survival in the sorafenib group.

In the SHARP study, patients were well balanced with respect to baseline characteristics (Table 1). As summarized in Table 2, this study demonstrated a significant improvement in median overall survival on sorafenib versus placebo (10.7 versus 7.9 months; hazard ratio [HR] in the sorafenib group 0.69; 95% CI 0.55–0.87; \(P < 0.001\)). There was significant prolongation of median time to radiologic progression in the sorafenib group (5.5 versus 2.8 months; \(P < 0.001\)). In the sorafenib group, seven patients (2.3%) had a partial response and 71 (71%) had stable disease (according to the Response Evaluation Criteria in Solid Tumors [RECIST]), whereas in the placebo group, two patients (1%) had a partial response and 204 patients (67%) had stable disease. There were no complete responses in either group. The disease-control rate, defined as complete/partial response or stable disease by RECIST for \(\geq 4\) weeks from the first demonstration of that rating, was significantly higher in the sorafenib group than in the placebo group (43% versus 32%; \(P = 0.002\)). Based on the SHARP data, sorafenib was approved by the European Medicines Agency in October 2007 and by the US Food and Drug Administration in November 2007 for the treatment of patients with unresectable HCC.

In order to achieve regulatory approval in China, Cheng et al conducted a Phase III randomized study comparing sorafenib with placebo in patients with advanced HCC in the Asia-Pacific region.\(^{37}\) This study had no predefined primary endpoint, and used the same eligibility criteria as the SHARP study. Two hundred and twenty-six patients in China, South Korea, and Taiwan were randomized on an intention-to-treat basis in a 2:1 ratio to sorafenib versus placebo. The number of patients needed for this study was calculated with a power of 83.9% to detect a 20% increase in overall survival in the sorafenib group. Overall survival, time to radiologic progression, time to symptomatic progression, disease-control rate, and safety were assessed. Patient characteristics and

### Table 1 Patient characteristics in SHARP and Asia-Pacific studies

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SHARP (n = 299)</th>
<th>Placebo (n = 303)</th>
<th>Asia-Pacific (n = 150)</th>
<th>Placebo (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years)</td>
<td>64.9</td>
<td>66.3</td>
<td>51</td>
<td>52</td>
</tr>
<tr>
<td>Male (%)</td>
<td>87</td>
<td>87</td>
<td>85</td>
<td>87</td>
</tr>
<tr>
<td>Europe/America/Asia; (%)</td>
<td>88/12/0</td>
<td>87/13/0</td>
<td>0/0/100</td>
<td>0/0/100</td>
</tr>
<tr>
<td>Hepatitis B/C status (%)</td>
<td>19/29</td>
<td>18/27</td>
<td>70.7/10.7</td>
<td>77.6/3.9</td>
</tr>
<tr>
<td>ECOG performance status 0, 1, or 2 (%)</td>
<td>54/38/8</td>
<td>54/39/7</td>
<td>26/69/5</td>
<td>28/67/5</td>
</tr>
<tr>
<td>BCLC Stage C (%)</td>
<td>82</td>
<td>83</td>
<td>95</td>
<td>96</td>
</tr>
<tr>
<td>Child-Pugh Class A/B (%)</td>
<td>95/5</td>
<td>98/2</td>
<td>97/3</td>
<td>97/3</td>
</tr>
<tr>
<td>Macropscopic vascular invasion (%)</td>
<td>36</td>
<td>41</td>
<td>36</td>
<td>34</td>
</tr>
<tr>
<td>Extrahepatic spread (%)</td>
<td>53</td>
<td>50</td>
<td>69</td>
<td>68</td>
</tr>
</tbody>
</table>

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Center.

### Table 2 Summary of outcome in SHARP and Asia-Pacific studies

<table>
<thead>
<tr>
<th>Efficacy parameter</th>
<th>SHARP</th>
<th>HR</th>
<th>Asia-Pacific</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sorafenib (n = 299)</td>
<td>Placebo (n = 303)</td>
<td>HR</td>
<td>Sorafenib (n = 150)</td>
</tr>
<tr>
<td>OS (months)</td>
<td>10.7</td>
<td>7.9</td>
<td>0.69 ((P &lt; 0.001))</td>
<td>6.5</td>
</tr>
<tr>
<td>TTP (months)</td>
<td>5.5</td>
<td>2.8</td>
<td>0.58 ((P &lt; 0.001))</td>
<td>2.8</td>
</tr>
<tr>
<td>TTSP (months)</td>
<td>4.1</td>
<td>4.9</td>
<td>1.08 ((P = 0.768))</td>
<td>3.5</td>
</tr>
<tr>
<td>DCR (%)</td>
<td>43</td>
<td>32</td>
<td>0.002 ((P = 0.0019))</td>
<td>35.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** HR, hazard ratio (sorafenib versus placebo); OS, overall survival; TTP, time to progression; TTSP, time to symptomatic progression; DCR, disease control rate.
efficacy outcomes are summarized in Tables 1 and 2. Overall survival was 6.5 months with sorafenib versus 4.2 months in the placebo group, with an HR of 0.68 ($P = 0.014$). Additionally, there were significant differences in time to radiologic progression and disease-control rate between the sorafenib and placebo groups, but not in time to symptomatic progression.

The Asia-Pacific study has confirmed the results of the SHARP study, and the magnitude of benefits in overall survival and time to radiologic progression derived from sorafenib was almost the same between these two studies, ie, a 31%–32% of relative risk reduction in death, and a 42%–43% relative benefit of increase in time to progression. However, the absolute benefit of the increase in overall survival and time to radiologic progression derived from sorafenib was smaller in the Asia-Pacific study than in the SHARP study. Additionally, the median overall survival and time to radiologic progression were shorter in Asia-Pacific study. There were more patients with HBV and severe disease, such as macroscopic vascular invasion and/or extrahepatic spread in the Asia-Pacific study, which might have contributed to the shorter overall survival and time to radiologic progression than were seen in the SHARP trial.

Patients with HBV-related HCC were shown to have poorer overall survival than patients with HCV-related HCC. In the SHARP study versus 18% in the SHARP trial. A subset analysis of 165 patients with HBV-related HCC in the Asia-Pacific study indicated that sorafenib improved overall survival and time to radiologic progression independent of HBV status, and the safety profile of sorafenib in patients with HBV was comparable with that for the overall study patients. In the SHARP study, 30% of patients were infected with HCV, and 25% had alcoholic liver disease. In a subset analysis of 178 patients with HCV-related HCC in the SHARP trial, overall survival was 14.0 months in 93 patients receiving sorafenib versus 7.9 months in 85 patients receiving placebo. The disease-control rate was higher in the sorafenib group compared with placebo (44% versus 31%). The safety profile of sorafenib treatment in patients with HCV-associated HCC was similar to that in all patients receiving sorafenib in this study.

The subgroup analysis in patients with alcohol-related HCC in the SHARP study demonstrated a similar outcome and safety profile to the overall population. Taken together, there is a consistent clinical benefit from sorafenib in HCC, irrespective of HBV/HCV status or alcoholic liver disease.

Combined analysis of the SHARP and Asia-Pacific trials to examine the effects of macroscopic vascular invasion, extrahepatic spread, and Eastern Cooperative Oncology Group (ECOG) performance status on outcome has shown that sorafenib was effective and safe for the treatment of advanced HCC in patients globally, irrespective of baseline ECOG performance status and the presence or absence of macroscopic vascular invasion and/or extrahepatic spread. In the SHARP study, 38% of patients had macroscopic vascular invasion and 52% had extrahepatic spread versus 35% with macroscopic vascular invasion and 68% with extrahepatic spread in the Asia-Pacific study (Table 1). However, a significant difference in overall survival based on the presence or absence of macroscopic vascular invasion and/or extrahepatic spread was observed in both trials. For patients treated with sorafenib in the SHARP study, median overall survival was 14.5 months in patients without macroscopic vascular invasion or extrahepatic spread versus 8.9 months with macroscopic vascular invasion and/or extrahepatic spread. For patients treated with sorafenib in the Asia-Pacific trial, median overall survival was 14.3 and 5.6 months, respectively. Therefore, for advanced HCC patients with macroscopic vascular invasion and/or extrahepatic spread, there is a dire need for treatment options in addition to sorafenib to improve the outcome.

Safety, tolerability, and patient-focused perspectives

As summarized in Table 3, the common drug-related adverse events in patients receiving sorafenib were hand-foot skin reaction, diarrhea, alopecia, fatigue, skin rash, hypertension, nausea, and anorexia. Hand-foot skin reaction and diarrhea were the two most frequent severe (Grade 3 or 4) toxicities in patients receiving sorafenib, at about 5%–10%. For patients on sorafenib, 26%–31% required dose reduction, and 20%–38% of patients terminated treatment due to toxicities. There seemed to be less treatment discontinuation in the Asia-Pacific study regardless of whether patients were on sorafenib or placebo than in the SHARP study.

There might be ethnic differences in hand-foot skin reaction, which occurred more frequently in Asian patients. Hand-foot skin reaction is manifested by formation of thick hyperkeratotic lesions affecting pressure points and flexure areas. These lesions usually develop after 2–4 weeks on sorafenib treatment and are often painful, which affects patient quality of life. A mild hand-foot skin reaction can be treated with lanolin-based or urea-based lotions. Protective measures, such as wearing gloves and socks, are recommended to provide pain relief and prevent skin breakdown. Dose reduction or interruption of sorafenib is frequently needed in patients...
with moderate to severe hand-foot skin reaction. Sorafenib can be resumed at a lower dose, with gradual escalation when hand-foot skin reaction is resolved.

Adverse cardiovascular toxicities, including myocardial infarction, hypertension, congestive heart failure, and arrhythmia, are frequently associated with antiangiogenic inhibitors, and are regarded as a class effect. Hypertension is the most frequent event, and most of the time is clinically manageable. The incidence of hypertension was 5% in the SHARP study and 19% in the Asia-Pacific study, with a 2% incidence of Grade 3 or 4 hypertension noted in sorafenib-treated patients in each of the studies. The incidence of severe cardiac ischemia or infarction in sorafenib-treated patients in each of the studies. The incidence of severe cardiac ischemia or infarction in sorafenib-treated patients in the SHARP study was 3% versus 1% in patients taking placebo. Sorafenib was associated with hypophosphatemia in 35% of sorafenib-treated patients compared with 11% taking placebo in the SHARP study. Grade 3 or 4 hypophosphatemia, which can lead to muscle weakness, altered mental status, and cardiac events, was seen in 11% of patients taking sorafenib. Therefore, sorafenib is not recommended in patients with a recent history of cardiac disease. All patients taking sorafenib should be monitored frequently for symptoms of cardiac disease and have blood levels monitored regularly for hypophosphatemia.

Hypothyroidism is a common side effect of sorafenib, and the incidence can be as high as 18%. Sorafenib can enhance T4 and T3 metabolism, which is probably caused by increased Type 3 deiodination. Clinical hypothyroidism occurs about one to seven months after the initiation of sorafenib. Therefore, it is important to monitor thyroid function periodically in patients receiving sorafenib. In the SHARP study, elevated lipase occurred in 40% of patients receiving sorafenib versus 37% for patients on placebo. However, Grade 3 or 4 lipase elevation was seen in 9% of patients receiving sorafenib. There have been cases reported of acute pancreatitis in patients receiving sorafenib treatment for HCC or renal cell carcinoma, and pancreatitis usually improves after stopping sorafenib.

There are limited data on the use of sorafenib in patients with Child-Pugh B or Child-Pugh C hepatic impairment. Yau et al reported a study involving 15 patients with Child-Pugh B/C cirrhosis receiving sorafenib for HCC. Thirteen patients discontinued treatment prematurely due to treatment toxicities. In a Phase II study of sorafenib in HCC, including 98 Child-Pugh A and 38 Child-Pugh B patients, there was no significant difference in sorafenib pharmacokinetics between patients with Child-Pugh A and Child-Pugh B impairment. However, Child-Pugh B patients had a higher rate of hyperbilirubinemia, encephalopathy, and worsening ascites, and Child-Pugh B patients did worse, with overall survival of 14 weeks versus 41 weeks for patients with Child-Pugh A. Therefore, it is recommended to reduce the starting dose, perhaps by 50%, with vigilant monitoring of liver function, if sorafenib is to be used in patients with Child-Pugh B liver cirrhosis. For HCC patients with Child-Pugh C, because of their severe underlying disease with limited life expectancy of usually less than three months, sorafenib treatment is not recommended.

In both the SHARP and Asian-Pacific studies, the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) was used to assess time to symptomatic progression. FHSI-8 is a patient-oriented outcome instrument designed to assess symptoms and quality of life in hepatobiliary cancer patients in general. FHSI-8 analyses in both studies failed to identify any significant difference between the sorafenib and placebo groups. The quality of life of these patients might have been affected by other concurrent diseases, such as liver cirrhosis. Additionally, FHSI-8 might not have

<table>
<thead>
<tr>
<th>Toxicities</th>
<th>SHARP</th>
<th>Placebo</th>
<th>Asia-Pacific</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sorafenib</td>
<td>Placebo</td>
<td>Sorafenib</td>
</tr>
<tr>
<td></td>
<td>All Grade 3/4</td>
<td>All Grade 3/4</td>
<td>All Grade 3/4</td>
</tr>
<tr>
<td>Hand-foot skin reaction</td>
<td>21%</td>
<td>8%</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>39%</td>
<td>8%</td>
<td>11%</td>
</tr>
<tr>
<td>Alopecia</td>
<td>14%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>22%</td>
<td>4%</td>
<td>16%</td>
</tr>
<tr>
<td>Rash/desquamation</td>
<td>16%</td>
<td>1%</td>
<td>11%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>16%</td>
<td>2%</td>
<td>11%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>14%</td>
<td>(&lt;1)</td>
<td>3%</td>
</tr>
<tr>
<td>Dose reduction*</td>
<td>26%</td>
<td>7%</td>
<td>31%</td>
</tr>
<tr>
<td>Drug discontination*</td>
<td>38%</td>
<td>37%</td>
<td>20%</td>
</tr>
</tbody>
</table>

Notes: *Variables are expressed as percentages; \(^{a}\)due to adverse events.
been sensitive enough to determine small but significant differences in quality of life between these two groups.

**Conclusion**

Sorafenib is the first agent that has resulted in a survival benefit in HCC, and has validated the role of targeted therapy in this disease. Its role in the management of advanced unresectable cancer is now well proven in all subpopulations of HCC having adequate hepatic reserve, and has been incorporated in the consensus-based treatment algorithm globally (see Figure 1 for a simplified schema).\(^{56-60}\) The role of sorafenib in HCC confined to the liver and as part of multimodality HCC treatment is currently under investigation. Ongoing studies will incorporate sorafenib with other treatment modalities, including transarterial chemoembolization, cytotoxic chemotherapy, surgery, and transplantation, in HCC patients.\(^{61}\) Further studies are needed to define its dosage and role in patients with Child-Pugh B and Child-Pugh C liver cirrhosis. Identification of a predictive biomarker signature will help to define the ideal patient population for sorafenib treatment in HCC.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


